Results 131 to 140 of about 93,221 (259)

A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer

The FEBS Journal, EarlyView.
Matrix metalloproteinases (MMPs) orchestrate cancer progression and metastasis through proteolytic and non‐proteolytic actions. By remodeling the tumor microenvironment, enhancing growth factor availability, and modulating cell behavior, MMPs promote proliferation, migration or invasion, and epithelial‐to‐mesenchymal transition. Alongside extracellular
Zoi Piperigkou, Sylvia Mangani, Spyros Kremmydas, Nikolaos E. Koletsis, Nikos K. Karamanos   +4 more
wiley   +1 more source

An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival. [PDF]

, 2019
BackgroundIn 2016, the World Health Organization reclassified the definition of glioblastoma (GBM), dividing these tumors into isocitrate dehydrogenase (IDH)-wild-type and IDH-mutant GBM, where the vast majority of GBMs are IDH-wild-type.
Barnholtz-Sloan, Jill S, Berger, Mitchel S, Chunduru, Pranathi, Cioffi, Gino, Gittleman, Haley, Molinaro, Annette M, Sloan, Andrew E   +6 more
core   +1 more source

Cellular Morphometric Analysis (CellMorph)—a comprehensive imaging‐based tool for quantifying cellular phenotype heterogeneity and dynamics across biological processes

The FEBS Journal, EarlyView.
CellMorph is a groundbreaking tool that allows researchers to analyze multiple features from single cells, including cell size and shape, cytosolic staining and subcellular texture, nuclear staining, and morphometry. By evaluating images from both bright‐field and fluorescence microscopy, it also tracks changes in living cells during key processes such
Henrique Quaiato de Oliveira, Solon Andrades da Rosa, Luiza Cherobini Pereira, Laura Boose de Mendonça, Juliete Scholl, Fabrício Figueiró, Thais Cardoso Bitencourt, Davi Piovesan Echevarria, João Luiz Aldinucci Buzzo, Jessica Boschini D'Agostin, Danieli Rosane Dallemole, Carolina Oliveira, Fernanda Simas, Fernanda Saez‐Calazans, Débora Santos‐Sousa, Guido Lenz, Eduardo C. Filippi‐Chiela   +16 more
wiley   +1 more source

hsa-miR-34a-5p enhances temozolomide anti-tumoral effects on glioblastoma

EXCLI Journal : Experimental and Clinical Sciences
Glioblastoma multiform (GBM) is a commonly diagnosed brain neoplasm with a poor prognosis. Accumulating evidence has highlighted the significance of microRNA (miR) dysregulation in tumor development and progression.
Mahdi Abdoli Shadbad, Amir Baghbanzadeh, Behzad Baradaran   +2 more
doaj   +1 more source

Glioblastoma mimicking anti‐NMDA receptor encephalitis: a case series

Internal Medicine Journal, EarlyView.
Abstract Anti‐N‐methyl‐D‐aspartate receptor (anti‐NMDAR) GluN1‐IgG antibodies are the hallmark of anti‐NMDAR encephalitis, a common type of autoimmune encephalitis. We describe two men with seizures and asymmetric, mass‐like temporal lesions initially treated as anti‐NMDAR encephalitis: Case 1 had serum and cerebrospinal fluid (CSF) NMDAR‐IgG ...
Sophie Chatterton, Fangzhi (Frank) Jia, Antonia J. Clarke, Laveniya Satgunaseelan, Hwei Choo Soh, Karl Ng, Kaitlyn Parratt, John Parratt   +7 more
wiley   +1 more source

Circadian rhythms in pediatric high-grade gliomas may contribute to treatment efficacy

Scientific Reports
Pediatric high-grade gliomas (pHGG) are highly invasive with poor survival outcomes. Timing of Temozolomide administration has been shown to affect survival of adult patients with glioblastoma.
Ella A. Nettnin, Cesar A. Garcia, Fudhial F. Sayed, Ethan Schonfeld, Thien Nguyen, Maria Isabel Barros Guinle, Claudia K. Petritsch, Erin M. Gibson, Laura M. Prolo   +8 more
doaj   +1 more source

Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models

Frontiers in Oncology
PurposeThe National Cancer Institute’s Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT) randomized phase 2 clinical trial assessed the utility of applying tumor DNA sequencing to treatment selection.
Yvonne A. Evrard, Sergio Y. Alcoser, Michael Mullendore, Li Chen, Chih-Jian Lih, Vishnuprabha Rahul Kannan, Vivekananda Datta, Lindsay Dutko, Shahanawaz Jiwani, Lawrence V. Rubinstein, Yingdong Zhao, P. Mickey Williams, Alida Palmisano, Alida Palmisano, Laura Kuhlmann, Mel Simpson, Shivaani Kummar, Biswajit Das, Chris Karlovich, Eric Polley, Ming-Chung Li, Alice P. Chen, Melinda G. Hollingshead, James H. Doroshow, James H. Doroshow   +24 more
doaj   +1 more source

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

International Journal of Cancer, Volume 158, Issue 12, Page 3217-3231, 15 June 2026.
What's new? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken, Seppo W. Langer, Geir Olav Hjortland, Anna Sundlöv, Eva Hofsli, Morten Ladekarl, Elizaveta Tabaksblat, Lene Weber Vestermark, Johanna Svensson, Ulrich Knigge, Luís Nunes, Bengt Glimelius, Per Pfeiffer, Kristine Aasebø, Jörg Assmus, Erik Vassella, Inger Marie Bowitz Lothe, Anne Couvelard, Aurel Perren, Stian Knappskog, Halfdan Sorbye   +20 more
wiley   +1 more source

The Dual Role of Autophagy in Cancer: Mechanisms and Therapeutic Strategies

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Autophagy is a conserved cellular process degrading dysfunctional organelles and protein aggregates to maintain cell homeostasis, and it exhibits context‐dependent duality in cancer. Autophagy functions as a critical tumor‐suppressive mechanism by preventing DNA damage and mutation during tumor initiation.
Xiang‐Zheng Gao, Yuheng Qin, Haoyu Wan, Guang Lu, Han‐Ming Shen   +4 more
wiley   +1 more source

Management of Adult Patients With Isocitrate Dehydrogenase‐Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro‐Oncology

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 392-403, June 2026.
Following maximal surgery when feasible, management of adult patients with isocitrate dehydrogenase (IDH)‐mutant glioma is complex and should be considered in a neuro‐oncology multidisciplinary context balancing disease control versus potential treatment‐associated toxicities. Options include continued surveillance, radiation therapy, chemotherapy, and/
Mark B. Pinkham, Hao‐Wen Sim, Rosalind L. Jeffree, Arian Lasocki, Dianne M. Legge, Frank Saran, Laveniya Satgunaseelan, Hui K. Gan   +7 more
wiley   +1 more source